A carregar...
Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4579903/ https://ncbi.nlm.nih.gov/pubmed/26622817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.3545 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|